Mature nodal T-cell lymphoma is a type of rare and aggressive blood cancer. Limited data make it difficult to identify high-risk patients or tailor treatment strategies, so most patients receive similar care despite differences in disease characteristics and outcomes. A new study led by investigators from PETAL Consortium at the Mass General Brigham Cancer Institute found that among patients who achieved a complete remission after initial chemotherapy treatment, survival was worse for those whose disease relapsed within 12 months of initial treatment, suggesting that alternative strategies are needed to benefit these patients. The results are published in Blood.

Recent advancements in pancreatic cancer prognosis have led to the development of the Tianjin Grading System, a tool integrating both anatomical resectability and tumor biological parameters. 

Researchers led by investigators at Mass General Brigham have published valuable information about a rare but serious complication of anti-cancer immunotherapy, providing the first large-scale description of its risk factors and clinical course, and underscoring the importance of early diagnosis and treatment. The findings are published in Blood and simultaneously presented at the American Society of Hematology Annual Meeting.